Hepatitis Diagnostic And Treatment Market Size, Share, Opportunities And Trends By Type (Diagnosis, Blood Test, DNA Test, Liver Biopsy, RNA Testing, Liver Ultrasound, Treatment, Drugs, Injectable Alpha Interferons, Liver Transplant), By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Others), And By Geography - Forecasts From 2019 To 2024

Published:  Mar 2020 Report Code: KSI061611513 Pages: 114

The hepatitis diagnostic and treatment market was valued at US$XX billion in 2017 and is projected to expand at a CAGR of XX.XX% over the forecast period to reach US$XX billion by 2023. Hepatitis means inflammation of the liver. There are several hepatitis viruses that have been categorized as Hepatitis A, B, C, D, E, and G and among them hepatitis A, B, and C are most common. According to World Health Organization’s global hepatitis report 2017, hepatitis B and C are responsible for 96% of all hepatitis mortality. Rising number of hepatitis infected population, growing consumption of alcohol and drugs and improved accessibility to hepatitis drug are the major factors that are driving the market’s growth. With new developments taking place in the treatment of hepatitis virus, and global players expanding their footprint across geographies to provide medication for the disease are the factors that will boost the hepatitis diagnostic and treatment market growth.

By Type

By type, the hepatitis diagnostic and treatment market has been broadly segmented into diagnostic and treatment. The hepatitis virus is diagnosed through various methods such as blood test, DNA test, Liver biopsy, RNA testing and liver ultrasound and is treated with drugs, injectable alpha interferons and in adverse cases liver transplant. Hepatitis B and C are considered as chronic viral hepatitis that are treated via antiviral medicines and injected alpha interferons.

By Disease Type

By disease type, the hepatitis diagnostic and treatment market has been segmented into Hepatitis A, B, C, and others. Others include Hepatitis D, E, and G. Hepatitis B and C are the most spread diseases around the world.  Hepatitis B is endemic in China and eastern Asia where most people become infected during childhood.

By Geography

Geographically, the hepatitis diagnostic and treatment market has been segmented into North America, Europe, Middle East & Africa, Asia-Pacific and South America region. North America accounts for the major share in the market owing to the advanced health infrastructure, accessibility of new drugs  and growing awareness among people about the disease.

Competitive Intelligence

The hepatitis diagnostic and treatment market is competitive owing to the presence of major players  and regional vendors in the market. The global key players are Novartis AG, F. Hoffmann-La Roche Ltd, Merk & Co., Inc., Vertex Pharmaceuticals Incorporated, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead, Bayer AG, AbbVie Inc., and Janssen Pharmaceuticals, Inc.

Segmentation

The hepatitis diagnostic and treatment market has been analyzed through following segments:

By Type

Diagnosis

Blood Test

DNA Test

Liver Biopsy

RNA Testing

Liver Ultrasound


Treatment

Drugs

Injectable alpha Interferons

Liver Transplant


By Disease Type

Hepatitis A

Hepatitis B

Hepatitis C

Others


By Geography

North America

United States

Canada

Mexico

Others


South America

Brazil

Argentina

Others


Europe

Germany

France

Italy

United Kingdom

Others


Middle East and Africa

Israel

Saudi Arabia

UAE

Others


Asia Pacific

Japan

China

India

Australia

South Korea

Others

Target audience

Manufacturers

Suppliers

Distributors

Service Providers

Government Agencies

Research Organizations

Consultants


Key insights offered in “Hepatitis Diagnostic and Treatment Market Report: Trends, Forecast and Competitive Analysis” 

What will be the hepatitis diagnostic and treatment market size from 2018 to 2023?

How are the major drivers and restraints affecting the hepatitis diagnostic and treatment market growth and the opportunities which exist for key vendors?

What are the business risks and threats involved in the hepatitis diagnostic and treatment market?

Which segment of the market and region will drive or lead the market growth and why?

A comprehensive analysis of competitive landscape and key market participants’ behavior

Key strategies being adopted by vendors, with in-depth analysis along with their impact on competition and market growth.

Analysis on growth opportunities in different applications and regions of hepatitis diagnostic and treatments.

Analysis of competitive intensity of the industry based on Porter’s Five force model

1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY 
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS

4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY TYPE 
5.1. Diagnosis
5.1.1. Blood Test
5.1.2. DNA Test
5.1.3. Liver Biopsy
5.1.4. RNA Testing
5.1.5. Liver Ultrasound
5.2. Treatment
5.2.1. Drugs
5.2.2. Injectable Alpha Interferons
5.2.3. Liver Transplant
6. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY DISEASE TYPE
6.1. Hepatitis A
6.2. Hepatitis B
6.3. Hepatitis C
6.4. Others
7. HEPATITIS DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY
7.1. North America
7.1.1. United States
7.1.2. Canada
7.1.3. Mexico
7.1.4. Others
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. Italy
7.3.4. United Kingdom
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Israel
7.4.2. Saudi Arabia
7.4.3. UAE
7.4.4. Others
7.5. Asia Pacific
7.5.1. Japan
7.5.2. China
7.5.3. India
7.5.4. Australia
7.5.5. South Korea
7.5.6. Others
8. COMPETITIVE INTELLIGENCE
8.1. Recent Deals and Investment
8.2. Strategies of Key Players
8.3. Investment Analysis
9. COMPANY PROFILES
9.1. Novartis AG
9.1.1. Company Overview
9.1.2. Financials
9.1.3. Products and Services
9.1.4. Recent Developments
9.2. F. Hoffmann-La Roche Ltd
9.2.1. Company Overview
9.2.2. Financials
9.2.3. Products and Services
9.2.4. Recent Developments
9.3. Merck & Co., Inc
9.3.1. Company Overview
9.3.2. Financials
9.3.3. Products and Services
9.3.4. Recent Developments
9.4. Vertex Pharmaceuticals Incorporated
9.4.1. Company Overview
9.4.2. Financials
9.4.3. Products and Services
9.4.4. Recent Developments
9.5. Bristol-Myers Squibb Company
9.5.1. Company Overview
9.5.2. Financials
9.5.3. Products and Services
9.5.4. Recent Developments
9.6. GlaxoSmithKline plc
9.6.1. Company Overview
9.6.2. Financials
9.6.3. Products and Services
9.6.4. Recent Developments
9.7. Gilead
9.7.1. Company Overview
9.7.2. Financials
9.7.3. Products and Services
9.7.4. Recent Developments
9.8. Bayer AG
9.8.1. Company Overview
9.8.2. Financials
9.8.3. Products and Services
9.8.4. Recent Developments
9.9. AbbVie Inc.
9.9.1. Company Overview
9.9.2. Financials
9.9.3. Products and Services
9.9.4. Recent Developments
9.10. Janssen Pharmaceuticals, Inc
9.10.1. Company Overview
9.10.2. Financials
9.10.3. Products and Services
9.10.4. Recent Developments
LIST OF FIGURES 
LIST OF TABLES

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us